Alexander Mark Schobel - Net Worth and Insider Trading

Alexander Mark Schobel Net Worth

The estimated net worth of Alexander Mark Schobel is at least $5 Million dollars as of 2024-11-29. Alexander Mark Schobel is the Chief Innovation/Tech Officer of Aquestive Therapeutics Inc and owns about 984,476 shares of Aquestive Therapeutics Inc (AQST) stock worth over $5 Million. Details can be seen in Alexander Mark Schobel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Alexander Mark Schobel has not made any transactions after 2024-03-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Alexander Mark Schobel

To

Alexander Mark Schobel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alexander Mark Schobel owns 1 companies in total, including Aquestive Therapeutics Inc (AQST) .

Click here to see the complete history of Alexander Mark Schobel’s form 4 insider trades.

Insider Ownership Summary of Alexander Mark Schobel

Ticker Comapny Transaction Date Type of Owner
AQST Aquestive Therapeutics Inc 2024-03-15 director & Chief Innovation/Tech Officer

Alexander Mark Schobel Latest Holdings Summary

Alexander Mark Schobel currently owns a total of 1 stock. Alexander Mark Schobel owns 984,476 shares of Aquestive Therapeutics Inc (AQST) as of March 15, 2024, with a value of $5 Million.

Latest Holdings of Alexander Mark Schobel

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AQST Aquestive Therapeutics Inc 2024-03-15 984,476 5.16 5,079,896

Holding Weightings of Alexander Mark Schobel


Alexander Mark Schobel Form 4 Trading Tracker

According to the SEC Form 4 filings, Alexander Mark Schobel has made a total of 8 transactions in Aquestive Therapeutics Inc (AQST) over the past 5 years, including 1 buys and 7 sells. The most-recent trade in Aquestive Therapeutics Inc is the sale of 50,000 shares on March 15, 2024, which brought Alexander Mark Schobel around $300,000.

Insider Trading History of Alexander Mark Schobel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Alexander Mark Schobel Trading Performance

GuruFocus tracks the stock performance after each of Alexander Mark Schobel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Alexander Mark Schobel is -1.2%. GuruFocus also compares Alexander Mark Schobel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Alexander Mark Schobel within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Alexander Mark Schobel's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Alexander Mark Schobel

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -17.63 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -12.21 LIMIT LIMIT LIMIT LIMIT LIMIT

Alexander Mark Schobel Ownership Network

Ownership Network List of Alexander Mark Schobel

No Data

Ownership Network Relation of Alexander Mark Schobel

Insider Network Chart

Alexander Mark Schobel Owned Company Details

What does Aquestive Therapeutics Inc do?

Who are the key executives at Aquestive Therapeutics Inc?

Alexander Mark Schobel is the director & Chief Innovation/Tech Officer of Aquestive Therapeutics Inc. Other key executives at Aquestive Therapeutics Inc include SVP & Operations Cassie Jung , Chief Medical Officer Carl N Kraus , and SVP & Research & Development Stephen Wargacki .

Aquestive Therapeutics Inc (AQST) Insider Trades Summary

Over the past 18 months, Alexander Mark Schobel made 2 insider transaction in Aquestive Therapeutics Inc (AQST) with a net sale of 75,000. Other recent insider transactions involving Aquestive Therapeutics Inc (AQST) include a net sale of 44 shares made by Cassie Jung ,

In summary, during the past 3 months, insiders sold 44 shares of Aquestive Therapeutics Inc (AQST) in total and bought 0 shares, with a net sale of 44 shares. During the past 18 months, 75,044 shares of Aquestive Therapeutics Inc (AQST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 75,044 shares.

Aquestive Therapeutics Inc (AQST)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aquestive Therapeutics Inc Insider Transactions

No Available Data

Alexander Mark Schobel Mailing Address

Above is the net worth, insider trading, and ownership report for Alexander Mark Schobel. You might contact Alexander Mark Schobel via mailing address: 30 Technology Drive, Warren Nj 07059.

Discussions on Alexander Mark Schobel

No discussions yet.